BRAF V600E
Braftovi Approved to Treat BRAF-Mutated CRC in Combination With Erbitux
The FDA approved the use of encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, ImClone) in ...
APRIL 21, 2020
Tafinlar + Mekinist, Companion Dx Approved for BRAF V600E–Mutant Metastatic NSCLC
Dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis) with Oncomine Dx Target Test ...
JUNE 23, 2017
Load more